Pharmacokinetic dosing in prophylactic treatment of hemophilia A, European Journal of Haematology, vol.13, issue.suppl 30, pp.247-252, 1993. ,
DOI : 10.1111/j.1600-0609.1993.tb00638.x
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A, Haemophilia, vol.3, issue.2, pp.96-101, 1997. ,
DOI : 10.1046/j.1365-2516.1997.00091.x
Pharmacokinetics of Coagulation Factors, Clinical Pharmacokinetics, vol.344, issue.11, pp.815-832, 2001. ,
DOI : 10.2165/00003088-200140110-00003
Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective, Haemophilia, vol.46, issue.s1, pp.101-110, 2003. ,
DOI : 10.1046/j.1365-2141.1996.d01-1705.x
Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia, Haemophilia, vol.104, issue.2, pp.571-582, 2005. ,
DOI : 10.1046/j.1365-2516.2003.00721.x
Effect of height and weight on the in vivo recovery of transfused factor VIII C., Journal of Clinical Pathology, vol.35, issue.3, pp.289-291, 1982. ,
DOI : 10.1136/jcp.35.3.289
Kinetic evaluation of four Factor VIII concentrates by model-independent methods, Scandinavian Journal of Haematology, vol.26, issue.Suppl, pp.22-28, 1985. ,
DOI : 10.1111/j.1600-0609.1985.tb00739.x
Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels, British Journal of Haematology, vol.70, issue.2, pp.474-476, 1995. ,
DOI : 10.1007/BF00637604
The half-life of infused factor VIII is shorter in hemophiliac patients with blood group 0 than in those with blood group A, Thromb Haemost, vol.83, pp.65-69, 2002. ,
Factor VIII half-life and clinical phenotype of severe hemophilia A, Haematologica, vol.90, pp.494-498, 2005. ,
) in children and causes of inter-patient pharmacokinetic variability, Haemophilia, vol.257, issue.1, pp.40-49, 2006. ,
DOI : 10.1016/S0955-3886(98)00024-1
Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII ? an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia, Haemophilia, vol.40, issue.s4, pp.50-55, 2006. ,
DOI : 10.2165/00003088-200140110-00003
In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting, Haemophilia, vol.87, issue.40, pp.2-8, 2007. ,
DOI : 10.1046/j.1365-2516.9.s1.4.x
Plasma and albumin-free recombinant factorVIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients, Journal of Thrombosis and Haemostasis, vol.3, issue.8, pp.1319-1326, 2008. ,
DOI : 10.1111/j.1538-7836.2008.03032.x
Population pharmacokinetics: theory and practice, Br J Clin Pharmacol, vol.32, pp.669-670, 1991. ,
The importance of modeling interoccasion variability in population pharmacokinetic analyses, Journal of Pharmacokinetics and Biopharmaceutics, vol.32, issue.6, pp.735-750, 1993. ,
DOI : 10.1007/BF01113502
Pharmacokinetics of Factor VIII in Humans, Clinical Pharmacokinetics, vol.22, issue.5, pp.385-395, 1992. ,
DOI : 10.2165/00003088-199222050-00005
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia, Haemophilia, vol.23, issue.2, pp.689-697, 2004. ,
DOI : 10.1111/j.1538-7836.2004.00528.x
Assay of Factor VIII:C with a Chromogenic Substrate, Scandinavian Journal of Haematology, vol.70, issue.S40, pp.139-145, 1984. ,
DOI : 10.1111/j.1600-0609.1984.tb02556.x
) NONMEM users guides, Icon Development Solutions, 1989. ,
Population pharmacokinetic studies in pediatrics: Issues in design and analysis, The AAPS Journal, vol.7, issue.2, pp.475-487, 2005. ,
DOI : 10.1208/aapsj070248
Xpose???an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM, Computer Methods and Programs in Biomedicine, vol.58, issue.1, pp.51-64, 1999. ,
DOI : 10.1016/S0169-2607(98)00067-4
Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects, Journal of Pharmacokinetics and Biopharmaceutics, vol.19, issue.5, pp.511-528, 1992. ,
DOI : 10.1007/BF01061469
Automated covariate model building within NONMEM, Pharmaceutical Research, vol.15, issue.9, pp.1463-1468, 1998. ,
DOI : 10.1023/A:1011970125687
Forecasting individual pharmacokinetics, Clinical Pharmacology & Therapeutics, vol.26, issue.3, pp.294-305, 1979. ,
DOI : 10.1002/cpt1979263294
)informativeness of empirical Bayes estimate-based diagnostics, AAPS J, vol.8, 2006. ,
Diagnosing Model Diagnostics, Clinical Pharmacology & Therapeutics, vol.23, issue.1, pp.17-20, 2007. ,
DOI : 10.1038/sj.clpt.6100241
A Limited Sampling Strategy for Estimating Individual Pharmacokinetic Parameters of Coagulation Factor VIII in Patients With Hemophilia A, Therapeutic Drug Monitoring, vol.29, issue.1, pp.20-26, 2007. ,
DOI : 10.1097/FTD.0b013e3180311384
The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications, Haemophilia, vol.3, issue.1, pp.1-8, 1997. ,
DOI : 10.1046/j.1365-2516.1997.00074.x
Clinical Pharmacokinetics of Factor VIII in Patients with Classic Haemophilia, Clinical Pharmacokinetics, vol.13, issue.6, pp.365-380, 1987. ,
DOI : 10.2165/00003088-198713060-00002
A Size Standard for Pharmacokinetics, Clinical Pharmacokinetics, vol.30, issue.5, pp.329-332, 1996. ,
DOI : 10.2165/00003088-199630050-00001
Human Recombinant DNA???Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A, New England Journal of Medicine, vol.323, issue.26, pp.1800-1805, 1990. ,
DOI : 10.1056/NEJM199012273232604
The pharmacokinetics of recombinant factor VIII, Semin Hematol, vol.28, pp.29-35, 1991. ,
Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil® M), Thrombos Haemostas, vol.68, pp.433-435, 1992. ,
A multicenter study of recombinant factor VIII (Recombinate?) in previously treated patients with hemophilia A, Thrombos Haemostas, vol.77, pp.660-667, 1997. ,
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen, Haemophilia, vol.43, issue.6, pp.753-760, 2002. ,
DOI : 10.1046/j.1365-2516.2000.00383.x
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A, Journal of Thrombosis and Haemostasis, vol.10, issue.Suppl. 4, pp.413-420, 2009. ,
DOI : 10.1111/j.1538-7836.2008.03270.x